CN116057067A - 用于治疗黑素瘤的ctl抗原的融合蛋白 - Google Patents

用于治疗黑素瘤的ctl抗原的融合蛋白 Download PDF

Info

Publication number
CN116057067A
CN116057067A CN202180043464.9A CN202180043464A CN116057067A CN 116057067 A CN116057067 A CN 116057067A CN 202180043464 A CN202180043464 A CN 202180043464A CN 116057067 A CN116057067 A CN 116057067A
Authority
CN
China
Prior art keywords
seq
clt
antigen
leu
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043464.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡西奥蒂斯
G·杨
J·阿蒂格
A·斯尼杰德
D·珀金斯
F·马里诺
R·贾普
M·冯埃森
P·马松
N·泰尔内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enara Biology Ltd
Francis Crick Institute Ltd
Original Assignee
Enara Biology Ltd
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enara Biology Ltd, Francis Crick Institute Ltd filed Critical Enara Biology Ltd
Publication of CN116057067A publication Critical patent/CN116057067A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180043464.9A 2020-04-17 2021-04-19 用于治疗黑素瘤的ctl抗原的融合蛋白 Pending CN116057067A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170174.5 2020-04-17
EP20170174 2020-04-17
PCT/US2021/028029 WO2021212123A1 (en) 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma

Publications (1)

Publication Number Publication Date
CN116057067A true CN116057067A (zh) 2023-05-02

Family

ID=70295067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043464.9A Pending CN116057067A (zh) 2020-04-17 2021-04-19 用于治疗黑素瘤的ctl抗原的融合蛋白

Country Status (6)

Country Link
US (1) US20230167163A1 (https=)
EP (1) EP4136097A1 (https=)
JP (1) JP2023522198A (https=)
CN (1) CN116057067A (https=)
CA (1) CA3179694A1 (https=)
WO (1) WO2021212123A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667288A (zh) * 2020-04-17 2023-01-31 弗朗西斯·克里克研究所有限公司 抗原池

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005338A2 (en) * 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295616A (zh) * 1998-02-05 2001-05-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
CN1315998A (zh) * 1998-07-14 2001-10-03 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
WO2006119527A2 (en) * 2005-05-11 2006-11-16 Avir Green Hills Biotechnology Research Development Trade Ag Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
CN101638440A (zh) * 2008-07-29 2010-02-03 中国人民解放军军事医学科学院基础医学研究所 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
BR112021006941A2 (pt) * 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
WO2021005338A2 (en) * 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295616A (zh) * 1998-02-05 2001-05-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
CN1315998A (zh) * 1998-07-14 2001-10-03 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
WO2006119527A2 (en) * 2005-05-11 2006-11-16 Avir Green Hills Biotechnology Research Development Trade Ag Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
CN101638440A (zh) * 2008-07-29 2010-02-03 中国人民解放军军事医学科学院基础医学研究所 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667288A (zh) * 2020-04-17 2023-01-31 弗朗西斯·克里克研究所有限公司 抗原池

Also Published As

Publication number Publication date
WO2021212123A1 (en) 2021-10-21
US20230167163A1 (en) 2023-06-01
EP4136097A1 (en) 2023-02-22
JP2023522198A (ja) 2023-05-29
CA3179694A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7762132B2 (ja) 新規な癌抗原及び方法
CN119119228A (zh) 新的癌抗原和方法
CN114341169B (zh) 新的癌抗原和方法
CN114174323B (zh) 新的癌抗原和方法
US20230167163A1 (en) Fusion proteins of ctl antigens for treating melanoma
JP7751817B2 (ja) 新規な癌抗原及び方法
US20230302109A1 (en) Antigen pool
EA052067B1 (ru) Новые раковые антигены и сопутствующие способы
EA052615B1 (ru) Новые раковые антигены и сопутствующие способы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination